Citation
Annual Financial Reports and Earnings Releases 2020-2024
TL;DR
BioNTech partnership initiated January 2020
Pfizer's financial reports document the fastest phototropic reorientation in pharmaceutical history - the COVID-19 vaccine development and manufacturing scale-up. The data shows $91B cumulative vaccine revenue (2020-2024), 50% manufacturing capacity reallocation, and $2B at-risk investment before approval.
These reports demonstrate how emergency gradient detection (global pandemic demand) translated into unprecedented resource reallocation speed, with the entire company bending toward a single product opportunity.
Key Findings from Inc. (2024)
- BioNTech partnership initiated January 2020
- $2B invested before FDA approval (at-risk capital)
- 50% manufacturing capacity shifted to COVID vaccine
- Peak revenue $37.8B (2022), cumulative ~$91B (2020-2024)